Literature DB >> 6251216

Immunological parameters in gestational trophoblastic neoplasia.

P C Ho, L W Mak, J W Lawton, H K Ma.   

Abstract

Immunological function were studied in 22 patients with hydatidiform mole and 29 patients with malignant trophoblastic disease before and after treatment; normal pregnant and post-pregnant women served as controls. The only significant abnormality in hydatidiform mole was a low granulocyte chemotaxis before evacuation. In malignant trophoblastic disease the total lymphocyte counts, T-cell counts. B-cell counts, lymphocyte responses to mitogens and serum IgA levels were significantly lower than in normal women 6 wk after pregnancy. In those who responded to chemotherapy, these indices rose to the levels of post-pregnancy controls. An 'immune profile score' based on these indices was found to be a useful prognostic index. All patients with hydatidiform mole who had a score of 7 or less developed malignant trophoblastic disease, while the two patients with malignant trophoblastic disease who died had the lowest scores of the series.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6251216     DOI: 10.1016/0165-0378(80)90004-2

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  3 in total

1.  Further studies on immunological parameters in gestational trophoblastic neoplasia.

Authors:  P C Ho; L C Wong; J W Lawton; H K Ma
Journal:  Arch Gynecol       Date:  1984

2.  NLRP7, a nucleotide oligomerization domain-like receptor protein, is required for normal cytokine secretion and co-localizes with Golgi and the microtubule-organizing center.

Authors:  Christiane Messaed; Elie Akoury; Ugljesa Djuric; Jibin Zeng; Maya Saleh; Lucy Gilbert; Muhieddine Seoud; Salman Qureshi; Rima Slim
Journal:  J Biol Chem       Date:  2011-10-24       Impact factor: 5.157

3.  A controlled trial of bestatin in hydatidiform mole.

Authors:  P C Ho; L C Wong; J W Lawton; H K Ma
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.